BOSTON — Adults with congenital adrenal hyperplasia receiving an oral nonsteroidal treatment saw a marked reduction in daily glucocorticoid dose at 24 weeks with maintenance of androgen control compared with placebo, researchers reported. The data suggest that the treatment, crinecerfont (Neurocrine Biosciences), a selective corticotropin-releasing factor type 1 receptor, could offer an